Trial Profile
PegIntron Injection Surveillance Plan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 10 Dec 2010 Actual initiation date changed from Aug 2006 to Jun 2006 as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.